Incorporated in 2009, Biolidics Limited (“Biolidics” or the “Company” and together with its subsidiaries the “Group”) focuses on developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.
To diversify our business model and build long term growth, the Group is also actively exploring technology-enabled lifestyle businesses, which would involve the ownership, operation and management of Multi-Channel Networks (“MCN”) businesses, live streaming social e-commerce platforms and Esports-related businesses.
Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.
Fully automated and entirely label-free, Biolidics’ ClearCell® FX1 System, with the patented microfluidic biochip, CTChip® FR1, the ClearCell® FX1 System achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer.
The wholly intact and viable CTCs isolated using our ClearCell® FX1 System are collected in a liquid suspension and can be transferred to various formats, such as glass slides and microtiter plates, for easy integration with routine pathology laboratory workflows.
18 Howard Road
#11-09 Novelty BizCentre,
Singapore 369585
Tel: 64820668
sales@biolidics.com
support@biolidics.com
Read more
